These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26379984)

  • 41. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Song MH; Ryu HW; Roh YJ
    Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
    Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab.
    Menezes C; Carvalho R; Teixeira C; Lemos JA; Gonçalves R; Coelho P; Lima A
    Case Rep Ophthalmol; 2015; 6(2):170-5. PubMed ID: 26120315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
    Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
    Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
    Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
    Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study.
    Tekin K; Sekeroglu MA; Cankaya AB; Teke MY; Doguizi S; Yilmazbas P
    Semin Ophthalmol; 2018; 33(2):265-270. PubMed ID: 27841949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
    Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
    Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
    Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
    Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
    Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
    Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.